Results 31 to 40 of about 22,681 (186)

EIF4A2 as another novel fusion partner of PLAG1 in lipoblastoma

open access: yesHuman Pathology Reports, 2022
The 5th edition of the WHO classification of Soft Tissue and Bone tumors recognizes lipoblastoma as a benign adipocytic tumor with excellent prognosis and a recurrence rate of 13–46%. The characteristic genomic alteration that helps separate lipoblastoma
Rofieda R. Alwaqfi   +2 more
doaj   +1 more source

Late widespread skeletal metastases from myxoid liposarcoma detected by MRI only [PDF]

open access: yes, 2008
Background Myxoid liposarcoma is the second most commonly occurring sub-type of liposarcomas. In contrast to other soft tissue sarcomas, it is known to have a tendency to spread toward extrapulmonary sites, such as soft tissues, retroperitoneum, and the
Lee A David   +20 more
core   +1 more source

Mutable and Slimy-Myxoid Pleomorphic Liposarcoma

open access: yesClinical Pathology & Research Journal, 2023
Myxoid pleomorphic liposarcoma is an exceptionally discerned, aggressive variant of liposarcoma predominantly incriminating young individuals. The preponderantly hybrid tumefaction demonstrates an amalgamation of morphological features of myxoid liposarcoma and pleomorphic liposarcoma.
openaire   +1 more source

Lipomatous Tumors in Pediatric Patients: A Retrospective Analysis of 50 cases

open access: yesTürk Patoloji Dergisi, 2020
Objective: Although lipomatous tumors are the most common type of mesenchymal tumors in adults, they account for less than 10% of all soft tissue lesions in pediatric patients.
Mine ÖZŞEN   +3 more
doaj   +1 more source

Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors [PDF]

open access: yesTürk Patoloji Dergisi, 2017
Objective: Programmed death ligand 1 (PD-L1) found on tumor cells has recently been reported to have a key role in the development and dissemination of many tumors, such as lung and breast carcinomas.
Kemal KÖSEMEHMETOĞLU   +4 more
doaj   +1 more source

Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma

open access: yesTherapeutic Advances in Medical Oncology, 2022
Liposarcoma (LPS) is a common soft tissue sarcoma that encompasses diverse subtypes of well-differentiated/dedifferentiated, myxoid/round cell, and pleomorphic LPS.
Prapassorn Thirasastr, Neeta Somaiah
doaj   +1 more source

Prognostic Factor Analysis and Nomogram Construction of Primary Retroperitoneal Liposarcoma: A Review of 10 Years of Treatment Experience in a Single Asian Cohort of 211 Cases

open access: yesFrontiers in Oncology, 2022
ObjectiveThis study intended to retrospectively analyze the data of patients with primary retroperitoneal liposarcoma in a single Asian large-volume sarcoma center and to establish nomograms focused on PRLPS for predicting progression-free survival (PFS)
Aobo Zhuang   +8 more
doaj   +1 more source

Liposarcoma of stomach: report of a case [PDF]

open access: yes, 1968
A report is made on a case of liposarcoma of stomach in a 42 year old man. This is the first case of liposarcoma of stomach reported in Japan. The patient has remained asymptomatic for five years after operation.
Orita, Kunzo   +4 more
core   +1 more source

p53 Expression in Canine Liposarcoma Correlates With Myxoid Variant and Higher Proliferative Activity [PDF]

open access: yes, 2020
Canine liposarcoma is classified as well differentiated (WDL), dedifferentiated (DDL), myxoid (ML), and pleomorphic (PL). Overexpression of the protooncogene MDM2 has been reported in WDL and DDL, but little is known regarding the role of p53 in their ...
Avallone G.   +6 more
core   +1 more source

Soft tissue tumors: Liposarcoma: Myxoid liposarcoma [PDF]

open access: yes, 2005
Review on Soft tissue tumors: Liposarcoma: Myxoid liposarcoma, with data on clinics, and the genes ...
Sánchez-Garcîa, I   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy